Table 3.
Multivariate analysis of prognostic factor for PFS and OS in FIGO stage III and IV (n = 47).
| Characteristics | Multivariate analysis of PFS | Multivariate analysis of OS | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age | ||||
| < 50 | 1 | 1 | ||
| ≥ 50 | 1.09 (0.47–2.52) | 0.842 | 1.00 (0.12–8.51) | 1.000 |
| CA-125 | ||||
| < 880 | 1 | 1 | ||
| ≥ 880 | 0.82 (0.32–2.11) | 0.686 | 0.64 (0.12–3.47) | 0.630 |
| TTC | ||||
| TTC < 12 | 1 | 1 | ||
| TTC ≥ 12 | 0.72 (0.29–1.78) | 0.470 | 0.84 (0.15–4.78) | 0.846 |
| Number of cycles of CTx | ||||
| 0 ~ 3 cycle | 1 | 1 | ||
| > 3 cycle | 0.49 (0.10–2.36) | 0.375 | 0.13 (0.01–1.18) | 0.070 |
| Residual disease | ||||
| No gross residual | 1 | 1 | ||
| Gross residual | 2.45 (0.99–6.05) | 0.045 | 3.60 (0.45–28.45) | 0.225 |
CTx. chemotherapy.